BioWorld
Other News to Note for Nov. 5, 2025
Polyactiva Pty Ltd., of Melbourne, Australia, and Raresight Inc., of Menlo Park, Calif., reported a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments. The research collaboration agreement, leveraging Polyactiva’s proprietary Prezia platform, will offer new chemical entity (NCE)-eligible pro-drug candidates to people affected by blinding eye conditions. Administered intravitreally, the approach will deliver sustained-release, zero-order treatment directly to the retina, requiring no patient administration — a key benefit for children and their caregivers.